NLS Norway

Uncategorized - January 13, 2014

Mapping reveals 110 MS-risk genes

Norwegian researchers have mapped genetic variations associated with an increased risk of multiple sclerosis (MS) and myasthenia gravis (MG), bringing science one step closer to understanding these serious autoimmune disorders. The Norwegian researchers have taken part in an international cooperative effort to map 110 genetic variations that increase the risk of MS and MG. Most […]

Drug Development Pharma - January 7, 2014

International pharmaceutical breakthrough backed by public funding

A multi-billion kroner agreement on a new pain-relief medication has been signed between the Norwegian innovation company, Inven2, and the pharmaceuticals giant, Merck. Public funding has played an important role in the Norwegian researchers’ success. The agreement confirms the vast potential of Norwegian health research. There are many outstanding researchers carrying out innovative basic and […]

Drug Development Pharma - December 13, 2013

Bayer granted marketing authorization in Norway for prostate cancer treatment

Bayer HealthCare announced recently that the company has received the marketing approval for Xofigo by the Norwegian Medicines Agency. Xofigo (radium Ra 223 dichloride) has been developed by Algeta. In September 2009, the two companies signed an agreement for the further development and commercialization of radium-223. Xofigo is produced in Norway at the Institute for Energy Technology (IFE) at […]

Clinical Trials - November 1, 2013

Important clinical trials in the North

Three major clinical trials in Norway will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis.  At the Norwegian Centre for Integrated Care and Telemedicine in Tromsø in Northern Norway, researchers will be studying the effects of telemedicine on people suffering from chronic obstructive pulmonary disease […]

Uncategorized - October 7, 2013

Individualized cancer treatment

The new Centre for Cancer Biomarkers (CCBIO) at the University of Bergen will conduct in-depth studies of the microenvironment of cancerous tumours, hunting for biomarkers to aid physicians in selecting the best targeted treatment. One of the CCBIO centre’s strengths is that its activities encompass the entire value chain from basic to applied research. Research […]

Uncategorized - September 29, 2013

The Norwegian centre CISMAC will combat threats to women’s and children’s health

The new Centre for Intervention Science in Maternal and Child Health (CISMAC) in Bergen is seeking to find ways to effectively increase survival and enhance maternal and child health. Each year, some seven million children in low- and middle-income countries (LMICs) die before the age of five, and close to 300 000 women lose their […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.